Aytu Biopharma, Inc. AYTU

Company Overview

Aytu BioPharma, Inc. (NASDAQ: AYTU) is a U.S.-based specialty pharmaceutical company focused on commercializing prescription therapeutics and consumer health products, primarily in the areas of central nervous system (CNS) disorders, pediatrics, and primary care. The company operates within the biopharmaceutical and healthcare industries, generating revenue through branded prescription medications, licensing arrangements, and consumer healthcare product sales. Its portfolio has included products targeting attention deficit hyperactivity disorder (ADHD), allergy-related conditions, and pediatric nutritional support. Aytu’s commercial strategy has historically emphasized acquiring or licensing underpromoted healthcare assets and leveraging a focused sales infrastructure to expand market penetration.

The company was formed in 2015 through the merger of Aytu BioScience, Inc. and Neos Therapeutics-related predecessor operations developed over subsequent years through acquisitions and licensing transactions. Aytu has evolved from a specialty pharmaceutical commercialization platform into a more diversified healthcare company with both prescription and over-the-counter product exposure. The company’s positioning has centered on niche therapeutics with established regulatory pathways and targeted physician engagement rather than large-scale drug discovery research.